SVP, Early Clinical Development
Arvinas
Essex, Connecticut, United States
Eric Masson PharmD, SVP Early Clinical Development, Arvinas
Eric Masson is a seasoned expert in drug development with extensive experience across various drug modalities and a strong focus on Model-Informed Drug Development (MIDD). With a Pharm.D. and post-doctoral fellowship in Clinical Pharmacology, he has held senior leadership roles at Arvinas, Biogen, AstraZeneca, and Bristol-Myers Squibb, where he led teams responsible for clinical pharmacology, pharmacometrics, and translational science. His work has significantly contributed to the development and approval of groundbreaking therapies in oncology, immunology, immuno-oncology and neuroscience, with a track record of successful IND/CTA submissions and global regulatory drug approvals.
He is currently SVP of Early Development at Arvinas leading teams responsible for non-clinical science, translational science, clinical pharmacology and pharmacometrics.
Disclosure(s): Arvinas: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Emerging New Therapeutic Modalities
Sunday, November 10, 2024
1:45 PM – 3:00 PM MST
Unique Model Informed Drug Development Opportunities with PROTAC Protein Degrader
Sunday, November 10, 2024
2:35 PM – 3:00 PM MST
